Specifically, the study seeks to quantitatively analyze Ki-67 expression across different tumor grades using immunohistochemistry and examine its relationship with key clinicopathological features, including hormone receptor status, HER2 expression, and lymph node involvement. Here, ERBB2 is linked to neoplasm.